This company has been marked as potentially delisted and may not be actively trading. XTL Biopharmaceuticals (XTLB) Short Interest Ratio & Short Volume Add Compare Share Share Short Interest Stock AnalysisCompetitorsEarningsHeadlinesShort InterestTrendsBuy This Stock XTL Biopharmaceuticals Short Interest DataXTL Biopharmaceuticals (XTLB) has a short interest of 48,000 shares. This marks a -11.28% decrease in short interest from the previous month. The short interest ratio (days to cover) is 6.1, indicating that it would take 6.1 days of the average trading volume of 19,651 shares to cover all short positions.Current Short Interest48,000 sharesPrevious Short Interest54,100 sharesChange Vs. Previous Month-11.28%Dollar Volume Sold Short$68,160.00Short Interest Ratio6.1 Days to CoverLast Record DateApril 30, 2025Outstanding Shares5,450,000 sharesPercentage of Shares Shorted0.88%Today's Trading Volume0 sharesAverage Trading Volume19,651 sharesToday's Volume Vs. Average0% Short Selling XTL Biopharmaceuticals? Sign up to receive the latest short interest report for XTL Biopharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartXTLB Short Interest Over TimeXTLB Days to Cover Over TimeXTLB Percentage of Float Shorted Over Time XTL Biopharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/202548,000 shares $68,160.00 -11.3%N/A6.1 $1.42 4/15/202554,100 shares $63,297.00 -1.1%1.4%10.4 $1.17 3/31/202554,700 shares $65,913.50 -2.8%1.4%9.4 $1.21 3/15/202556,300 shares $69,249.00 -17.3%1.5%6.7 $1.23 2/28/202568,100 shares $92,275.50 -16.0%1.8%6.5 $1.36 2/15/202581,100 shares $133,085.10 -4.1%2.1%8.1 $1.64 1/31/202584,600 shares $138,321.00 -7.1%N/A7.8 $1.64 1/15/202591,100 shares $169,446.00 -1.1%N/A2.1 $1.86 12/31/202492,100 shares $171,306.00 +30.1%N/A2.1 $1.86 12/15/202470,800 shares $127,440.00 -5.6%N/A1.7 $1.80 Get the Latest News and Ratings for XTLB and Related StocksEnter your email address below to receive the latest news and analysts' ratings for XTL Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 11/30/202475,000 shares $141,000.00 -0.3%N/A1.9 $1.88 11/15/202475,200 shares $138,368.00 -64.8%N/A1.9 $1.84 10/31/2024213,400 shares $475,882.00 +2,381.4%N/A5.4 $2.23 10/15/20248,600 shares $19,092.00 -41.5%N/A1 $2.22 9/30/202414,700 shares $35,574.00 +51.6%N/A1.4 $2.42 9/15/20249,700 shares $25,501.30 +1.0%N/A0.9 $2.63 8/31/20249,600 shares $26,784.00 -7.7%N/A0.6 $2.79 8/15/202410,400 shares $29,016.00 +103.9%N/A0.6 $2.79 7/31/20245,100 shares $14,688.00 -64.3%N/A0.3 $2.88 7/15/202414,300 shares $35,607.00 -19.2%N/A0.8 $2.49 6/30/202417,700 shares $43,011.00 +78.8%N/A0.8 $2.43 6/15/20249,900 shares $20,196.00 -55.0%N/A0 $2.04 5/31/202422,000 shares $57,200.00 -13.4%N/A0 $2.60 5/15/202425,400 shares $69,596.00 +13.4%N/A0 $2.74 4/30/202422,400 shares $57,792.00 -62.8%N/A0 $2.58 4/15/202460,200 shares $161,336.00 -86.2%N/A0.1 $2.68 3/31/2024437,200 shares $1.23 million +21,760.0%N/A0.6 $2.81 3/15/20242,000 shares $1,760.00 +11.1%N/A0 $0.88 2/29/20241,800 shares $1,531.26 -37.9%N/A0.6 $0.85 2/15/20242,900 shares $2,608.26 -42.0%N/A0.9 $0.90 1/31/20245,000 shares $4,378.50 -27.5%N/A1.4 $0.88 1/15/20246,900 shares $6,009.90 +1.5%N/A1.9 $0.87 12/31/20236,800 shares $6,868.68 -32.7%N/A1.7 $1.01 12/15/202310,100 shares $9,965.67 -15.8%N/A3.9 $0.99 11/30/202312,000 shares $12,360.00 +36.4%N/A5.7 $1.03 11/15/20238,800 shares $6,864.00 -24.8%N/A2.7 $0.78 10/31/202311,700 shares $10,148.58 +62.5%N/A3.2 $0.87 10/15/20237,200 shares $6,480.00 -22.6%N/A1.3 $0.90 9/30/20239,300 shares $8,347.68 -3.1%N/A1.7 $0.90 9/15/20239,600 shares $9,311.04 +29.7%N/A1.5 $0.97Buffett’s favorite chart just hit 209% – here’s what that means for gold (Ad)A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time is about to validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.Be ready before the historic gold move. Get Garrett’s Top Four picks now. 8/31/20237,400 shares $7,770.00 +236.4%N/A0.5 $1.05 8/15/20232,200 shares $2,086.26 +29.4%N/A0.2 $0.95 7/31/20231,700 shares $1,385.84 -19.1%N/A0.1 $0.82 7/15/20232,100 shares $2,142.00 -16.0%N/A0.1 $1.02 6/30/20232,500 shares $2,376.75 -28.6%N/A0.2 $0.95 6/15/20233,500 shares $4,620.00 -25.5%N/A0.2 $1.32 5/31/20234,700 shares $5,734.00 +27.0%N/A0.6 $1.22 5/15/20233,700 shares $4,477.00 +23.3%N/A0.5 $1.21 4/30/20233,000 shares $3,360.00 -55.2%N/A0.5 $1.12 4/15/20236,700 shares $8,241.00 -23.0%N/A1.7 $1.23 3/31/20238,700 shares $11,049.00 +117.5%N/A4.1 $1.27 3/15/20234,000 shares $4,920.00 +2.6%N/A1.6 $1.23 2/28/20233,900 shares $5,459.61 -7.1%N/A1.3 $1.40 2/15/20234,200 shares $5,586.00 -16.0%N/A1.5 $1.33 1/31/20235,000 shares $5,850.00 -12.3%N/A1.4 $1.17 1/15/20235,700 shares $7,866.00 +2,750.0%N/A1.7 $1.38 12/30/2022200 shares $242.00 -95.7%N/A0.1 $1.21 12/15/20224,700 shares $5,687.00 -6.0%N/A1 $1.21 11/30/20225,000 shares $6,650.00 +6.4%N/A1.2 $1.33 11/15/20224,700 shares $6,674.00 +261.5%N/A1 $1.42 10/31/20221,300 shares $1,677.00 -40.9%N/A0.3 $1.29 10/15/20222,200 shares $2,651.00 +83.3%N/A0.3 $1.21 9/30/20221,200 shares $1,332.00 -77.4%N/A0.2 $1.11 9/15/20225,300 shares $7,155.00 -22.1%N/A0.9 $1.35 8/31/20226,800 shares $10,064.00 +4.6%N/A1.2 $1.48 8/15/20226,500 shares $11,115.00 +8.3%N/A1.2 $1.71 7/31/20226,000 shares $9,780.00 -25.9%N/A1.1 $1.63 7/15/20228,100 shares $12,231.00 +42.1%N/A2.9 $1.51 6/30/20225,700 shares $8,664.00 +11.8%N/A1.7 $1.52 6/15/20225,100 shares $7,854.00 -13.6%N/A1.5 $1.54 5/31/20225,900 shares $10,714.99 -37.2%N/A0.9 $1.82 5/15/20229,400 shares $15,886.00 +20.5%N/A1.5 $1.69 4/30/20227,800 shares $17,160.00 +9.9%N/A1.4 $2.20 4/15/20227,100 shares $16,685.00 +16.4%N/A1.2 $2.35 3/31/20226,100 shares $14,457.00 +96.8%N/A0.9 $2.37 3/15/20223,100 shares $6,616.95 +121.4%N/A0.3 $2.13 2/28/20221,400 shares $3,332.00 -17.7%N/A0.1 $2.38 2/15/20221,700 shares $4,114.00 No ChangeN/A0.1 $2.42 1/31/20221,700 shares $4,284.00 -56.4%N/A0.1 $2.52 1/15/20223,900 shares $11,349.00 -17.0%N/A0.1 $2.91 12/31/20214,700 shares $13,019.00 +147.4%N/A0.2 $2.77 12/15/20211,900 shares $5,567.00 -64.2%N/A0.1 $2.93 11/30/20215,300 shares $16,960.00 +960.0%N/A0.2 $3.20 11/15/2021500 shares $1,790.00 -58.3%N/A0 $3.58 10/29/20211,200 shares $4,584.00 -60.0%N/A0 $3.82 10/15/20213,000 shares $11,790.00 -85.2%N/A0 $3.93 9/30/202120,200 shares $88,476.00 +1.0%N/A0.1 $4.38 9/15/202120,000 shares $82,800.00 -68.7%N/A0.1 $4.14 8/31/202163,900 shares $316,305.00 +75.6%N/A0.4 $4.95 8/13/202136,400 shares $129,220.00 -15.7%N/A0.3 $3.55Elon just did WHAT!? (Ad)As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they gotten away with it, the Fed and U.S. banks could have seized control of our financial lives forever. But Trump stopped them cold on January 23rd, 2025, when he outlawed CBDCs… Paving the way for Elon Musk's secret master plan.Click here to see how to claim your stake before they launch to avoid missing out. 7/30/202143,200 shares $151,200.00 +37.6%N/A0.5 $3.50 7/15/202131,400 shares $108,958.00 -35.3%N/A0.4 $3.47 6/30/202148,500 shares $193,515.00 +40.2%N/A3.4 $3.99 6/15/202134,600 shares $119,370.00 -2.8%N/A2.1 $3.45 5/28/202135,600 shares $125,682.24 +14.8%N/A1.5 $3.53 5/14/202131,000 shares $103,230.00 -19.7%N/A0.1 $3.33 4/30/202138,600 shares $137,416.00 -5.6%N/A0.1 $3.56 4/15/202140,900 shares $132,516.00 -1.2%N/A0.2 $3.24 3/31/202141,400 shares $136,206.00 -19.8%N/A0.2 $3.29 3/15/202151,600 shares $174,924.00 +719.1%N/A0.2 $3.39 2/26/20216,300 shares $19,152.00 -77.7%N/A0 $3.04 2/12/202128,200 shares $106,596.00 +464.0%N/A1 $3.78 1/29/20215,000 shares $16,100.00 -76.5%N/A0.2 $3.22 1/15/202121,300 shares $84,135.00 +88.5%N/A0.8 $3.95 12/31/202011,300 shares $35,764.50 -76.6%N/A0.4 $3.17 12/15/202048,200 shares $126,766.00 +518.0%N/A2.5 $2.63 11/30/20207,800 shares $19,573.32 -34.5%N/A0.5 $2.51 10/30/20206,900 shares $15,318.00 -46.1%N/A0.4 $2.22 10/15/202012,800 shares $27,904.00 -14.1%N/A0.7 $2.18 9/30/202014,900 shares $28,308.51 +156.9%N/A0.9 $1.90 9/15/20205,800 shares $12,586.00 +65.7%N/A0.3 $2.17 8/31/20203,500 shares $5,950.00 +483.3%N/A0.1 $1.70 8/14/2020600 shares $1,032.00 -45.5%N/A0 $1.72 7/31/20201,100 shares $1,732.50 -93.3%N/A0.1 $1.58 7/15/202016,400 shares $25,060.84 +198.2%N/A0.9 $1.53 6/30/20205,500 shares $8,525.00 -16.7%N/A0.3 $1.55 6/15/20206,600 shares $9,075.00 -7.0%N/A0.4 $1.38 5/29/20207,100 shares $9,744.75 -47.0%N/A2.1 $1.37 XTLB Short Interest - Frequently Asked Questions What is XTL Biopharmaceuticals' current short interest? Short interest is the volume of XTL Biopharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of April 30th, investors have sold 48,000 shares of XTLB short. Learn More on XTL Biopharmaceuticals' current short interest. What is a good short interest ratio for XTL Biopharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. XTLB shares currently have a short interest ratio of 6.0. Learn More on XTL Biopharmaceuticals's short interest ratio. Is XTL Biopharmaceuticals' short interest increasing or decreasing? XTL Biopharmaceuticals saw a drop in short interest in April. As of April 30th, there was short interest totaling 48,000 shares, a drop of 11.3% from the previous total of 54,100 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does XTL Biopharmaceuticals' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to XTL Biopharmaceuticals: CytoMed Therapeutics Limited (1.47%), Tempest Therapeutics, Inc. (3.29%), Cara Therapeutics, Inc. (1.74%), Pulmatrix, Inc. (0.65%), KALA BIO, Inc. (7.62%), CASI Pharmaceuticals, Inc. (0.19%), Enlivex Therapeutics Ltd. (0.58%), ABVC BioPharma, Inc. (2.18%), Clene Inc. (2.79%), ALX Oncology Holdings Inc. (17.78%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Spotify Technology S.A. ($4.67 billion), Charter Communications, Inc. ($4.58 billion), Capital One Financial Co. ($4.47 billion), The Kroger Co. ($2.56 billion), Reddit, Inc. ($2.23 billion), Rivian Automotive, Inc. ($2.16 billion), Live Nation Entertainment, Inc. ($1.90 billion), SoFi Technologies, Inc. ($1.85 billion), Zscaler, Inc. ($1.75 billion), and Omnicom Group Inc. ($1.75 billion). View all of the most shorted stocks. What does it mean to sell short XTL Biopharmaceuticals stock? Short selling XTLB is an investing strategy that aims to generate trading profit from XTL Biopharmaceuticals as its price is falling. XTLB shares are trading down $0.03 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against XTL Biopharmaceuticals? A short squeeze for XTL Biopharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of XTLB, which in turn drives the price of the stock up even further. How often is XTL Biopharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including XTLB, twice per month. The most recent reporting period available is April, 30 2025. More Short Interest Resources from MarketBeat Related Companies CytoMed Therapeutics Short Squeeze Tempest Therapeutics Short Squeeze Cara Therapeutics Short Squeeze Pulmatrix Short Squeeze KALA BIO Short Squeeze CASI Pharmaceuticals Short Squeeze Enlivex Therapeutics Short Squeeze ABVC BioPharma Short Squeeze Clene Short Squeeze ALX Oncology Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:XTLB) was last updated on 5/23/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XTL Biopharmaceuticals Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share XTL Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy XTLB Stock Free XTLB Stock Alerts